Lykiri, I totally agree with you.
Meirluc continually states as facts things that are not facts and that I'm almost sure are not true.
One of his statements I don't agree with (and doesn't make any sense to me) is that the rGBM arm patients had a higher mOS than the nGBM arm patients. Actually, the numbers suggest exactly the opposite, as follows from a very simple math exercise, based on information from the final results presentation:
- From slide 39, mOS for rGBM patients is 13.2 months from recurrence
- From slide 3,"Time to tumor recurrence: ~7-8 months from surgery"
If we add 7.5 months (average time from surgery to recurrence from above) to 13.2 monhts (mOS from recurence) we get 20.7 months mOS for rGBM patients from surgery.
From slide 29, mOS from surgery for nGBM patients is 22.4 months, which is clearly higher than mOS from surgery for rGBM patients of 20.7 months.
He also keeps stating that the 64 rGBM patients in the trial are or may not be comparable with the ECAs, which is not true, as clearly mentioned in the same presentation, slides 15, 16, 17 and 21.
Regarding your question to him, I don't think the mOS of the 35 patients (that are not part of neither of the nGBM and rGBM arms) is as he states because, as I have mentioned in other posts, I think those 35 patients have a higher percentage of IDH mutated than the other groups and that actually is correlated to not having progressed. Also, after some math I shared in previous posts I think in those 35 patients there is a higher percentage of MGMT methylated than in the nGBM and rGBM arms (also related to lower progression) and finally I also think there is a possibility that some of those 35 patients received DCVax that actually helped them but, were not real progressors (could have been pseudoprogressors form SOC) or didn't classify to the rGBM arm for any other reason.
** Sorry for any inconvenience, but English is not my native language
